TRDA
Entrada Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.85 / 10
Netural
Liquidity flow is robust with a 7.69/10 score, reflecting good fund activity despite mixed directional trends (positive small/large flows vs. negative overall/block flows). Analyst coverage is minimal—only one active analyst with a Strong Buy rating—and historical prediction accuracy is low (0.0% win rate), underscoring uncertainty in the consensus view.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-05-20
InstitutionHC Wainwright & Co.
Times predicted4
Historical Win Rate0.0%
Is money flowing into or out of TRDA?
- TRDA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.85/10 (Netural).
